Journal of Clinical Oncology
Articles in this Issue
Disitamab vedotin (RC48), tislelizumab, and S-1 as first-line therapy for HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Updated survival and exploratory biomarker results from the RCTS trial.
4065 Background: Anti-PD1 antibody has significantly improved survival in patients with HER2-overexpressing and PD-L1 comb...
Trajectories of circulating epithelial tumor cells for early prostate cancer detection.
e17118 Background: Prostate cancer is a major cause of cancer-related mortality among older men, highlighting the need for...
Deficiencies in oncology marketing applications leading to FDA rejections: An assessment of complete response letters.
e23048 Background: The U.S. Food and Drug Administration (FDA) issues Complete Response Letters (CRLs) to notify sponsors...
Age-specific risks of leukemia in Li Fraumeni syndrome in children, adolescents, young adults, and adults.
e22653 Background: Leukemia is a well-recognized risk in Li Fraumeni Syndrome (LFS), but age-specific risks in males and f...
The price of a breath: The economic and mortality burden of checkpoint inhibitor pneumonitis (2016–2020).
12142 Background: The landscape of oncologic toxicity has drastically changed because of the rapid introduction of Immune...
Temporal changes in the algebraic connectivity of collateral sensitivity maps.
e15007 Background: Drug resistance remains one of the greatest challenges in oncology, often limiting the long-term effica...
Neoadjuvant chemotherapy with NALIRIFOX for locally advanced colorectal cancer: A multicenter, single-arm, phase II trial.
e15638 Background: Dual-agent regimens such as CAPOX and FOLFOX have demonstrated significant tumor downstaging efficacy i...
A four-subtype model of cervical cancer based on <i>PIK3CA</i> mutation, <i>STK11</i> mutation or deletion, and <i>YAP1</i> amplification: Multiple PI3K pathway inhibitors as suppressors of growth and cooperators with HPV-directed immunotherapy.
e17522 Background: Cervical cancer is driven by human papillomavirus (HPV) infection yet lacks molecularly defined subtype...
Delivering complex pancreatic cancer care locally: Five-year FOLFIRINOX outcomes from Northern Ireland.
e16358 Background: Combination chemotherapy (FOLFIRINOX) improves survival in metastatic pancreatic cancer, with PRODIGE4/...
Adjuvant durvalumab or tislelizumab combined with S-1 for resected high-risk biliary tract cancers in China: A multicenter, two-cohort, single-arm, open-label, phase 2 trial preliminary analysis.
e16275 Background: Patients with biliary tract cancer (BTC) have a poor prognosis and high postoperative recurrence rates....
Myxoid/round cell liposarcoma misdiagnosis incidence, etiology, and importance of NY-ESO-1 testing: Retrospective analysis of the Tempus database.
11542 Background: Liposarcoma is composed of multiple unique sarcoma subtypes, specifically myxoid/round cell liposarcoma...
The HER2 paradox in ovarian clear cell carcinoma: Expression and intrinsic resistance to trastuzumab deruxtecan (T-DXd).
5563 Background: Trastuzumab deruxtecan (T-DXd) shows potent activity in HER2-expressing ovarian cancer (OC). However, eff...
Health-related quality of life (HRQoL) with neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin ineligible: Phase 3 KEYNOTE-905 study.
4510 Background: In KEYNOTE-905/EV-303 (NCT03924895), neoadj-adj EV + pembro and radical cystectomy (RC) + pelvic lymph no...
The oncology data paradigm in practice: A feasibility study of structured data capture with minimal support (stage one of a multi-phase implementation).
e13660 Background: We previously showed success with collection of structured data elements within the electronic health r...
The electronic frailty index used to identify high-risk older adults receiving chimeric antigen receptor T-cell therapy.
11009 Background: Chimeric antigen receptor T-cell therapy (CAR-T) has transformed outcomes in relapsed/refractory hematol...
Impact of body composition on prognosis, treatment toxicity, and surgical complications in locally advanced gastric cancer.
e16128 Background: Weight loss and skeletal muscle wasting are frequent in cancer and may influence treatment tolerance an...
Association of immunotherapy infusion timing with outcomes in early-stage triple-negative breast cancer.
594 Background: Circadian regulation of immune function has been shown to influence the efficacy of immune checkpoint inhi...
Ethnicity-based comparative analysis of treatment endpoints of 30,000 HR+/HER2− metastatic breast cancer patients on CDK4/6 inhibitors (palbociclib/ribociclib/abemaciclib).
1085 Background: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), in combination with endocrine therapy, are the mainstay...
Longitudinal epigenome-wide associations and pre-chemotherapy prediction of post-chemotherapy inflammation in patients with breast cancer undergoing chemotherapy.
e24094 Background: Inflammation is linked with cancer outcomes; systemic cytokine levels are associated with cognitive and...
Carfilzomib-based combinations for Waldenström macroglobulinemia: Real-world experience from a single center.
e19080 Background: Waldenström Macroglobulinemia (WM) is the most common lymphoplasmacytic lymphoma (LPL). Bortezomib is a...
Impact of racial and socioeconomic factors on cutaneous B-cell lymphoma survival: A SEER analysis.
e19063 Background: Primary cutaneous B-cell lymphomas (PCBCL), primary cutaneous diffuse large B-cell lymphoma (PCDLBCL),...
Patient-reported experience of home-based oncology care among privately funded UK-based patients: Results from a multi-modal outreach survey.
e13603 Background: Home-based oncology services can reduce treatment burden, but patient experience data for privately fun...
Real-world genetic testing patterns in prostate cancer assessed via artificial intelligence: Implications for NCCN guideline implementation.
5022 Background: Germline and somatic genomic testing in prostate cancer guide both targeted therapy selection and identif...
Benchmarking next-generation large language models (LLMS): Evaluation of patient-oriented prostate cancer guidance.
e17116 Background: Large language models (LLMs) are increasingly used by patients to seek medical information, including c...
Integrated analysis of the ropeginterferon alfa-2b clinical program in essential thrombocythemia to demonstrate molecular and hematologic responses with safety profile information across treatment lines, ethnicities, and driver mutation types.
6576 Background: Patients with essential thrombocythemia (ET) have limited disease-modifying options. This integrated anal...